BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...cGMP levels and patients exhibited no adverse events.Intra-Cellular Therapies Inc....
...where the MOA involves preventing breakdown of cGMP. Intra-Cellular...
...—the company’s primary focus.  In June, Intra-Cellular...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

...and Amgen both said COVID-19 had affected new patient starts.Similarly, 2Q sales of Caplyta lumateperone from Intra-Cellular Therapies Inc....
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...board of PureTech Health plc (LSE:PRTC). Mazumdar-Shaw is the co-founder and executive chairperson of Biocon Ltd. (NSE:BIOCON; BSE:532523).Intra-Cellular...
BioCentury | Sep 9, 2020
Product Development

Intra-Cellular eyes broad label for bipolar depression after Phase III hit

...By Lauren Martz, Senior Editor Intra-Cellular added $903.9...
...submission planned for late 2020 or early 2021.Intra-Cellular Therapies Inc....
...III monotherapy trials that read out last year (see “Intra-Cellular...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...CSO by Kimberly Vanover, who was SVP, early stage clinical development and translational medicine at Intra-Cellular Therapies Inc....
...hired Eve Taylor as VP, clinical development. She was senior director of clinical development at Intra-Cellular...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...Investors view FDA’s willingness to consider aducanumab and its recent approval of Caplyta lumateperone from Intra-Cellular Therapies Inc....
...to treat schizophrenia based on a combination of late-stage hits and misses. The approval sent Intra-Cellular’s...
BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...Intra-Cellular raises $295M In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the...
...Intra-Cellular’s close at $30.62 on Monday, when the company proposed the offering after market hours. Intra-Cellular...
...Morgan, SVB Leerink, Evercore, Cantor Fizgerald, Canaccord Genuity and JMP Securities (see “Unanticipated Approval Lifts Intra-Cellular...
BioCentury | Dec 23, 2019
Company News

Caplyta’s unanticipated schizophrenia approval lifts Intra-Cellular shares

...Emerging from a cloud of regulatory questions and mixed clinical results, Intra-Cellular has received FDA approval...
...a Phase III miss left investors unsure about the drug’s odds of approval. In August, Intra-Cellular Therapies Inc....
...readout (see “Intra-Cellular Optimistic on Lumateperone’s Future in Bipolar Despite Mixed Phase III Results” ). Intra-Cellular...
BioCentury | Sep 11, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

...patients with advanced solid tumors, excluding brain cancers. Intra-Cellular issues FDA update on lumateperone NDA Intra-Cellular Therapies Inc....
...FDA's request for additional toxicology information on the product. The PDUFA date is Dec. 27. BC Staff Intra-Cellular Therapies Inc. Lexicon...
BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

...candidate is a designed ankyrin repeat protein that antagonizes VEGF-A. Delay for Intra-Cellular's schizophrenia NDA Intra-Cellular Therapies Inc....
...patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) sintilimab (IBI308) tafasitamab (MOR00208, MOR208, xmab5574) Allergan plc Alnylam Pharmaceuticals Inc. GW Pharmaceuticals plc Innovent Biologics Inc. Intra-Cellular Therapies Inc. Molecular...
Items per page:
1 - 10 of 109
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...cGMP levels and patients exhibited no adverse events.Intra-Cellular Therapies Inc....
...where the MOA involves preventing breakdown of cGMP. Intra-Cellular...
...—the company’s primary focus.  In June, Intra-Cellular...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

...and Amgen both said COVID-19 had affected new patient starts.Similarly, 2Q sales of Caplyta lumateperone from Intra-Cellular Therapies Inc....
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...board of PureTech Health plc (LSE:PRTC). Mazumdar-Shaw is the co-founder and executive chairperson of Biocon Ltd. (NSE:BIOCON; BSE:532523).Intra-Cellular...
BioCentury | Sep 9, 2020
Product Development

Intra-Cellular eyes broad label for bipolar depression after Phase III hit

...By Lauren Martz, Senior Editor Intra-Cellular added $903.9...
...submission planned for late 2020 or early 2021.Intra-Cellular Therapies Inc....
...III monotherapy trials that read out last year (see “Intra-Cellular...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...CSO by Kimberly Vanover, who was SVP, early stage clinical development and translational medicine at Intra-Cellular Therapies Inc....
...hired Eve Taylor as VP, clinical development. She was senior director of clinical development at Intra-Cellular...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...Investors view FDA’s willingness to consider aducanumab and its recent approval of Caplyta lumateperone from Intra-Cellular Therapies Inc....
...to treat schizophrenia based on a combination of late-stage hits and misses. The approval sent Intra-Cellular’s...
BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...Intra-Cellular raises $295M In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the...
...Intra-Cellular’s close at $30.62 on Monday, when the company proposed the offering after market hours. Intra-Cellular...
...Morgan, SVB Leerink, Evercore, Cantor Fizgerald, Canaccord Genuity and JMP Securities (see “Unanticipated Approval Lifts Intra-Cellular...
BioCentury | Dec 23, 2019
Company News

Caplyta’s unanticipated schizophrenia approval lifts Intra-Cellular shares

...Emerging from a cloud of regulatory questions and mixed clinical results, Intra-Cellular has received FDA approval...
...a Phase III miss left investors unsure about the drug’s odds of approval. In August, Intra-Cellular Therapies Inc....
...readout (see “Intra-Cellular Optimistic on Lumateperone’s Future in Bipolar Despite Mixed Phase III Results” ). Intra-Cellular...
BioCentury | Sep 11, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

...patients with advanced solid tumors, excluding brain cancers. Intra-Cellular issues FDA update on lumateperone NDA Intra-Cellular Therapies Inc....
...FDA's request for additional toxicology information on the product. The PDUFA date is Dec. 27. BC Staff Intra-Cellular Therapies Inc. Lexicon...
BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

...candidate is a designed ankyrin repeat protein that antagonizes VEGF-A. Delay for Intra-Cellular's schizophrenia NDA Intra-Cellular Therapies Inc....
...patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) sintilimab (IBI308) tafasitamab (MOR00208, MOR208, xmab5574) Allergan plc Alnylam Pharmaceuticals Inc. GW Pharmaceuticals plc Innovent Biologics Inc. Intra-Cellular Therapies Inc. Molecular...
Items per page:
1 - 10 of 109